About the Journal
Focus and Scope
Cancer and Tumor Review is an international Open Access journal that publishes articles related to all areas of cancers and tumors. The topics of interest include but not limited to diagnosis, therapy, imaging, prevention, quality of life, supportive care, education and awareness.
Peer Review Process
All manuscripts submitted to Whioce Publishing Pte. Ltd. will follow the following procedure:
- Initial submission are reviewed by in-house editors to ensure adherence to journal policies
- Editor-in-chief decides on the manuscript to be sent out for review process and assigns the manuscript to one of the editors according to the particular topic.
- Editor assigns reviewers from inside the editorial board or outside depending on the topic.
- After evaluations by the reviewers have been received, the editor-in-chief makes one of the following recommendations: accept, minor revision, major revision, reject and resubmit, and reject. Unless otherwise requested by the Editor-in-Chief, the following time frames will be used.
- If decision is “minor revision”, the authors have 4 weeks to resubmit the revised manuscript.
- If decision is “major revision”, the authors have 2 months to resubmit the revised manuscript.
- Upon resubmission, the same procedure is applied as for the initial submission.
- Authors may appeal for a rejected submission. Appeal requests must be made in writing to editorial@whioce.com with detailed reasons for the appeal and point by point responses to the reviewer’s remarks. Decisions on appeals are final without exception.
- For all manuscripts accepted for publication, the peer review process will be deemed to be completed. The manuscript will proceed to be copyedited, layout edited and proofread before being published online.
Publication Frequency
quarterly
Open Access Policy
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Recently Published Articles
Original Research Article by Kaplan Mones, Denburg Liguoro Cancer and Tumor Review 2017, 1(1); Most of the enzymes are proteins and there are a few macromolecules with biocatalytic activity such as RNA and DNA. Ribozyme (Rz) is a class of biocatalytic RNA. The substrate is a ribozyme of the RNA molecule that catalyzes the cleavage and splicing of the substrate RNA. Its role is characterized by low cutting efficiency and is easily destroyed by RNase. The catalytic type includes RNA transnucl… |
Original Research Article by Cheng Guodong, Wu Ping, Zhou Fengzhi, Guan Yi Cancer and Tumor Review 2017, 1(1); Objective: To investigate the changes of cell cycle and the content of P53 protein in S180 cells by using the specific fluorescent probe to identify the biological target to be measured according to the change of the fluorescence signal. The results showed that Shikonin had good anti-tumor effect. Methods: Cell cycle changes and P53 protein content in S180 cells were detected by flow cytometry. Re… |
Original Research Article by Yue Mingzhu, Liu lu, Fan Cheng, Zhai Haizhi Cancer and Tumor Review 2017, 1(1); Purpose: (1) To investigate the expression of CaSR in papillary thyroid carcinoma, thyroid benign lesion and normal thyroid cells by immunohistochemistry and to analyze the relationship between CaSR and papillary thyroid carcinoma. (2) To study the difference of the expression of thyroid papillary carcinoma between calcification group and thyroid papillary carcinoma without calcification and the d… |
Original Research Article by Gang Yan,Hongyu Gao,Baochu Ding,Jiaming Yu Cancer and Tumor Review 2017, 1(1); Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. It is also a high incidence of malignancy in our country. It is difficult to be diagnosed early, and it is easy to relapse and metastasis after operation. At present, liver cancer is still recognized as the preferred surgical treatment and the main treatment, but because many patients with liver cancer … |
Original Research Article by Zhao Xinran, Li Qi, Cai Chengchuan Cancer and Tumor Review 2017, 1(1); Objective: To perform PICC catheterization in 129 hospitalized patients with chemotherapy for infusion of chemotherapy. The clinical response of patients with PICC after catheterization is to find out the causes of complications and to give appropriate care. This is to investigate the causes and nursing strategies of common complications after PICC catheterization in patients with chemotherapy. Me… |
Authorship
Authorship should be limited to people who have contributed substantially to the work. Authors must indicate their specific contributions to the published work. This information should be listed in the manuscript under the section ‘Author Contribution’. Examples of contributions include: designed research, performed research, contributed new reagents or analytic tools, analyzed data, wrote the paper. For more information on submission’s format, please refer to the ‘Author Guidelines’ link accessible from the ‘About’ button at the top row of this page. The corresponding author should be clearly indicated for all manuscripts submitted. A maximum of two corresponding authors are allowed for the responsibilities associated. The corresponding author(s) is responsible for: Obtaining permission from all the authors mentioned in the manuscript Ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication Including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g. data from manuscripts-in-press, personal communication, or work in preparation.
Conflict of Interest
The author has to provide the authorization of no conflict with any financial body or funding agency that might influence the results or interpretation of their manuscript. Any conflict of interest on the part of author(s) must be declared within the submitted manuscript before being published. Apart from authors, members, reviewers and editors must also disclose any association that poses a conflict of interest in connection with the manuscript.
Plagiarism
The editorial team does not approve of any plagiarism attempts. Plagiarism detection software will be utilized at the editor’s discretion to verify the originality of submitted manuscripts. If plagiarism is detected during the review process the manuscript may be rejected depending on the severity of plagiarism. Therefore, if a manuscript uses a text copied directly from another source, this text must be written in quotation marks and the original source must be cited.
Publication Fees
The publication fees for each manuscript accepted for publication is USD 800 for 6 pages. This fee is meant to support the open access journal’s associated expenses. The editorial team will have the right to assume that authors submitting their manuscripts for publication consents to paying the publication fee upon acceptance for publication unless given a written waiver from both the Editor-in-Chief and the Publisher.
Language
All articles should be written in English—either British or American as long as consistency is observed. SI units should be used. If you are not a native English speaker, you may want to utilize an external or Whioce Publishing’s optional professional language editing service before submitting the final version.
Language Editing Services
Whioce Publishing Pte Ltd offers its own professional editing services. By using this service, you can be sure that your English-language manuscript will be polished and ready for submission to your publication of choice at a very reasonable price. For further details about the Language Editing Services, please contact us at academic@whioce.com. Please note that utilizing a language editing service is not a guarantee of acceptance.
Editorial Board
Click here to see the editorial board members.
Indexing and Archiving
Cancer and Tumor Review (CTR) aims to be indexed by world-recognized databases, for example, PubMed, Scopus and Science Citation Index (SCI).
